• OPEN AN ACCOUNT
Indian Indices
Sensex
80,722.94 -1,546.84
( -1.88%)
Global Indices
Nasdaq
48,928.31 -164.26
(-0.33%)
Dow Jones
6,963.16 -26.85
(-0.38%)
Hang Seng
53,392.10 16.50
(0.03%)
Nikkei 225
10,214.90 43.14
(0.42%)
Forex
USD-INR
91.92 0.08
(0.09%)
EUR-INR
109.97 0.03
(0.03%)
GBP-INR
126.94 0.27
(0.21%)
JPY-INR
0.60 0.00
(0.00%)

EQUITY - MARKET SCREENER

Vilin Bio Med Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
78871
INE0L4V01013
16.5329749
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
VILINBIO
218.75
48.83
EPS(TTM)
Face Value()
Div & Yield %
0.16
10
0
 

mangalam organics ltd
Dr Reddy’s Swiss subsidiary gets USFDA CRL for biosimilar AVT03
Jan 01,2026
AVT03 is a proposed biosimilar to Amgen’s Prolia and Xgeva and has been developed by Alvotech hf. According to the company, the CRL pertains to observations made by the US Food and Drug Administration (USFDA) during a pre-licence inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland.

Hyderabad-based Dr. Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company’s consolidated net profit jumped 7.3% to Rs 1,347.10 crore on a 9.8% increase in revenue from operations to Rs 8,804.90 crore in Q2 FY26 over Q2 FY25.

The counter slipped 1.66% to Rs 1,250 on the BSE.